Your browser doesn't support javascript.
loading
Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2, and lymphokine-activated killer cells versus adriamycin alone.
Kawata, A; Une, Y; Hosokawa, M; Wakizaka, Y; Namieno, T; Uchino, J; Kobayashi, H.
Affiliation
  • Kawata A; First Department of Surgery, Hokkaido University School of Medicine, Sapporo, Japan.
Am J Clin Oncol ; 18(3): 257-62, 1995 Jun.
Article in En | MEDLINE | ID: mdl-7747715
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Immunotherapy, Adoptive / Interleukin-2 / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Clin Oncol Year: 1995 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Doxorubicin / Immunotherapy, Adoptive / Interleukin-2 / Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Clinical_trials / Observational_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Am J Clin Oncol Year: 1995 Document type: Article Affiliation country: Japón Country of publication: Estados Unidos